1964: Discovery and Development of Propranolol (1964)

In the early 1960s, ischaemic heart disease was the leading cause of death in industrialised nations,
yet pharmacological options to prevent angina pectoris were limited to nitrates and were not
mechanism-directed. James Black, working at ICI Pharmaceuticals in Cheshire, England, reasoned
from Ahlquist's receptor classification that selective blockade of cardiac beta-1 adrenoreceptors
would reduce myocardial oxygen demand by lowering heart rate and contractility—thus relieving
exercise-induced angina without the non-selective sympathetic effects of earlier compounds.

Black's team synthesised propranolol (ICI 45520) in 1962, and clinical trials initiated in 1964
confirmed its efficacy in angina pectoris. The compound also demonstrated antihypertensive and
antiarrhythmic properties that broadened its clinical utility considerably. Propranolol received
FDA approval in 1967 as the first beta-blocker to reach the US market.

Subsequent clinical evidence—particularly the Beta Blocker Heart Attack Trial (BHAT, 1982) and
other trials—established beta-blockers as a cornerstone of secondary prevention after myocardial
infarction, reducing mortality by 20–25%. They became standard of care in heart failure, atrial
fibrillation, and hypertension, and remain among the most prescribed cardiovascular drugs worldwide.

James Black was awarded the Nobel Prize in Physiology or Medicine in 1988, shared with George
Hitchings and Gertrude Elion. In his Nobel lecture, Black articulated the principle of rational
drug design based on receptor pharmacology—design a molecule that selectively engages a defined
receptor to produce a predictable therapeutic effect—a principle that had been implicit in
pharmacology but was first fully realised with propranolol.